A Phase 1 interventional study of BMS-986278 and Placebo in Healthy Volunteers, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-03.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the effect of BMS-986278 on the cardiac repolarization in healthy participants.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BMS-986278
Drug: BMS-986278 · Drug: Placebo
Drug: Placebo
Drug: Placebo · Drug: Moxifloxacin
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Change from baseline Fridericia's corrected QT interval (QTcF) (ΔQTcF)
Time frame: Up to Day 13
Placebo-corrected change from baseline QTcF (ΔΔQTcF)
Time frame: Up to Day 13
Change from baseline heart rate (HR)
Time frame: Up to Day 13
Placebo-corrected change from baseline HR
Time frame: Up to Day 13
Change from baseline PR interval
Time frame: Up to Day 13
Placebo-corrected change from baseline PR interval
Time frame: Up to Day 13
Change from baseline QRS interval
Time frame: Up to Day 13
Placebo-corrected change from baseline QRS interval
Time frame: Up to Day 13
Number of participants with categorical outliers for QTcF
Time frame: Up to Day 13
Number of participants with categorical outliers for HR
Time frame: Up to Day 13
Number of participants with categorical outliers for PR interval
Time frame: Up to Day 13
Number of participants with categorical outliers for QRS interval
Time frame: Up to Day 13
Number of participants with treatment-emergent changes of electrocardiogram (ECG) morphology
Time frame: Up to Day 13
Change from baseline QTcF (ΔQTcF)
Time frame: Up to Day 13
Placebo-corrected change from baseline QTcF (ΔΔQTcF)
Time frame: Up to Day 13
Number of participants with non-serious adverse events (AEs)
Time frame: Up to approximately 17 weeks
Number of participants with Serious AEs (SAEs)
Time frame: Up to approximately 17 weeks
Number of participants with AEs leading to study intervention discontinuation
Time frame: Up to approximately 17 weeks
Number of participants with vital sign abnormalities
Time frame: Up to approximately 17 weeks
Number of participants with clinical laboratory assessment abnormalities
Time frame: Up to approximately 17 weeks
Number of participants with 12-lead ECG abnormalities
Time frame: Up to approximately 17 weeks
Number of participants with physical examination abnormalities
Time frame: Up to approximately 17 weeks
Maximum observed concentration (Cmax)
Time frame: Up to Day 13
Time of maximum observed concentration (Tmax)
Time frame: Up to Day 13
Area under the concentration-time curve in 1 dosing interval (AUC[TAU])
Time frame: Up to Day 13
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Ran from Feb 2026 to primary completion in Jun 2026, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Admilparant · Moxifloxacin